Sandoz has announced that the Mexican health authority, COFEPRIS, has approved the company’s marketing application for the Airflusal Forspiro salmeterol/fluticasone DPI for the treatment of asthma and for COPD. Three dosage levels were approved: 50-100 µg, 50-250 µg and 50-500 µg. The product will be marketed as IrFlosol Forspiro in Mexico.
The Mexican approval of Airflusal is the first in Latin America. The DPI is approved in a number of European countries and in South Korea.
Sandoz Head of Global Respiratory Jan-Torsten Tews said, “We look forward to launching Airflusal Forspiro in Mexico in the near future and making this important respiratory product available to those suffering from asthma and COPD. Airflusal Forspiro is an affordable and award winning new option, developed in close collaboration with patients.”
Read the Sandoz press release.
